Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates

Caribou Biosciences, Inc.

Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.
Cash, equivalents, and marketable securities $372.4M at Dec 31, 2023, up from $317.0M; expected to fund operations into Q1 2026.
CB-010: 30th patient dosed in ANTLER dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024.
CB-012: First patient dosed in AMpLify Phase 1 trial for r/r AML.
CB-020 preclinical anti-ROR1 CAR-NK program paused; CB-011 enrollment continues at dose level 3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 11, 2024, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a business update.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.